the discovery and development of liraglutide and semaglutide A Novel Method for Synthesis Purification - Barredo‐Vacchelli - 2024 - Peptide Science Liraglutide & Semaglutide: Exploring Biosimilar

Not for human or veterinary use.

Understanding this nuanced relationship helps patients and clinicians make informed decisions about GLP-1 therapy while protecting vision through appropriate monitoring and individualized treatment approaches

Risk factors for NAION: Age (usually affects people over 50) Diabetes Hypertension High cholesterol Sleep apnea Anatomical predispositions (such as a small cup-to-disc ratio) Symptoms of NAION include sudden vision loss in one eye (ranging from mild to severe), missing portions of vision (visual field defects), and disc swelling

Prefer convenience

A 2025 study in JAMA Network Open showed that adults using semaglutide or tirzepatide had lower risks of dementia, stroke, and all-cause mortality compared with people taking other diabetes medications